en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Guide › Background And Research Context — Complete Guide

Background And Research Context — Complete Guide

By Editorial Desk · published 2026-02-01 · last reviewed 2026-03-19 · Guide

metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Related pages on this site

Mechanism And Metabolic Effects

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Identity And Research Background

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Background and Molecular Identity

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Further detail

== Laser == Laser blepharoplasty is the performance of eyelid surgery using a laser instead of a scalpel. Laser blepharoplasty is often combined with laser eyelid rejuvenation, as the two procedures can be performed in conjunction. A CO2 laser blepharoplasty offers many benefits over a blepharoplasty performed using a scalpel. Some of these benefits include less bleeding, shortened surgical time, better intraoperative visibility, less bruising and swelling, less pain or discomfort, and smoother healing. Historically there has been some contention as to the categorization of laser treatment on upper or lower eyelids as blepharoplasty, which is itself by definition surgical. The statutory definition of surgery and that supported by the American College of Surgeons states that surgery is the "treatment ... by any instrument causing localized alteration or transportation of live human tissue, which include lasers".

=== Legacy === A research center that was planned in the 1970s was opened in 1975 (CBM) in the Autonomous University of Madrid (UAM). After his death, it was named the Centro de Biología Molecular Severo Ochoa. In Leganés, Madrid, a hospital bears his name, as does the Madrid Metro station serving it, Hospital Severo Ochoa. The asteroid 117435 Severochoa is also named in his honor. In 2003, the Spanish General Post Office (Correos) issued a €0,76 postage stamp honoring Ochoa, as one of a pair featuring Spanish medical Nobel Prize winners alongside Santiago Ramón y Cajal. In June 2011, the United States Postal Service issued a stamp honoring him, as part of the American Scientists collection, along with Melvin Calvin, Asa Gray, and Maria Goeppert-Mayer. This was the third volume in the series. The main road in to the tourist resort Benidorm is named Avenida Dr. Severo Ochoa in his honor.

Compounds of vitamin B6 contain a pyridine ring. The actual active compound is pyridoxal phosphate. However, pyridoxal as well as pyridoxine, pyridoxamine, and their phosphates can readily be converted into pyridoxal phosphate. Consequently, all six compounds are assigned to the vitamin B6 group. In humans, pyridoxal phosphate acts as a cofactor in a very large number of biological processes, including approximately 140 known enzymatic reactions. About 4% of all cellular enzymes require pyridoxal phosphate as a cofactor. Vitamin B6 must be obtained from the diet and is found in substantial amounts in both animal and plant foods. Animal sources include fish, liver, and other offal. Plant sources include potatoes, nuts, avocados, and bananas. In plant foods, the vitamin B6 precursor pyridoxine-5'-glucoside predominates. The principal function of pyridoxal phosphate in these reactions is the stabilization of negative charges in amino compounds. Such reactions include transaminations, decarboxylations, as well as various substitution reactions and elimination reactions. Nicotinamide adenine dinucleotide (NAD) is likewise a cofactor and is essential for many redox reactions in biological systems. These include the degradation of glucose to pyruvic acid during glycolysis. NAD is also required for the citrate cycle. In addition, it acts as a regulator of transcription factors, for example in the circadian rhythm.

The first Waffle House opened on Labor Day weekend in 1955 at the location 2719 East College Avenue in Avondale Estates, Georgia. That restaurant was conceived and founded by Joe Rogers Sr. and Tom Forkner. Rogers started in the restaurant business as a short-order cook in 1947 at the Toddle House in New Haven, Connecticut. By 1949, he had become a regional manager with the now-defunct Memphis-based Toddle House chain. He then moved to Atlanta, where he met Tom Forkner while buying a house from him in Avondale Estates. Rogers's concept was to combine the speed of fast food with table service with around-the-clock availability. Forkner suggested naming the restaurant "Waffle House", as waffles were the most profitable item on the 16-item menu. Rogers continued to work with Toddle House, and, to avoid conflict of interest, sold his interest to Forkner in 1956.

Sources: en.wikipedia.org

Supporting material

Argon is a chemical element; it has symbol Ar and atomic number 18. It is in group 18 of the periodic table and is a noble gas. Argon is the third most abundant gas in Earth's atmosphere, at 0.934% (9340 ppmv). It is more than twice as abundant as water vapor (which averages about 4000 ppmv, but varies greatly), 23 times as abundant as carbon dioxide (400 ppmv), and more than 500 times as abundant as neon (18 ppmv). Argon is the most abundant noble gas in Earth's crust, comprising 0.00015% of the crust. Nearly all argon in Earth's atmosphere is radiogenic argon-40, derived from the decay of potassium-40 in Earth's crust. In the universe, argon-36 is by far the most common argon isotope, as it is the most easily produced by stellar nucleosynthesis in supernovas. The name "argon" is derived from the Ancient Greek word ἀργόν, neuter singular form of ἀργός meaning 'lazy' or 'inactive', as a reference to the fact that the element undergoes almost no chemical reactions. The complete octet (eight electrons) in the outer atomic shell makes argon stable and resistant to bonding with other elements. Its triple point temperature of 83.8058 K is a defining fixed point in the International Temperature Scale of 1990. Argon is extracted industrially by the fractional distillation of liquid air. It is mostly used as an inert shielding gas in welding and other high-temperature industrial processes where ordinarily unreactive substances become reactive; for example, an argon atmosphere is used in graphite electric furnaces to prevent the graphite from burning.

It is cleared from the body by tubular secretion and excreted unchanged in the urine; it is undetectable in blood plasma within 24 hours of a single oral dose. The average elimination half-life in plasma is 6.2 hours. Metformin is distributed to (and appears to accumulate in) red blood cells, with a much longer elimination half-life: 17.6 hours (reported as ranging from 18.5 to 31.5 hours in a single-dose study of nondiabetics). Some evidence indicates that liver concentrations of metformin in humans may be two to three times higher than plasma concentrations, due to portal vein absorption and first-pass uptake by the liver in oral administration.

=== Metabolism === Nicotine decreases hunger and as a consequence food consumption, alongside increasing energy expenditure. The majority of research shows that nicotine reduces body weight, but some researchers have found that nicotine may result in weight gain under specific types of eating habits in animal models. Nicotine effect on weight appears to result from nicotine's stimulation of α3β4 nAChR receptors located in the POMC neurons in the arcuate nucleus and subsequently the melanocortin system, especially the melanocortin-4 receptors on second-order neurons in the paraventricular nucleus of the hypothalamus, thus modulating feeding inhibition. POMC neurons are a precursor of the melanocortin system, a critical regulator of body weight and peripheral tissue such as skin and hair.

Sources: en.wikipedia.org

Supporting material

Ten years earlier, in 2005, the Minnesota Department of Health notified the federal Centers for Disease Control and Prevention (CDC) that four cases of Salmonella typhimurium (S. typhimurium) with an indistinguishable pulsed-field gel electrophoresis (PFGE) subtype (CDC PulseNet pattern JPXX01.1173) had been identified. The only common exposure among the four ill individuals was that all had eaten at one of two Cold Stone Creamery stores. All cases had eaten cake batter flavor ice cream in the week before the onset of symptoms. After a thorough investigation, 25 cases were identified in nine states (Minnesota, Oregon, Washington, Virginia, Ohio, California, Illinois, Massachusetts, Michigan, and Pennsylvania); 24 reported eating cake batter ice cream from Cold Stone Creamery.

In the United States, pine nuts are mainly harvested by Native American and Hispano communities, particularly in the Western United States and Southwestern United States, by the Shoshone, Paiute, Navajo, Pueblo, Hopi, Washoe, and Hispanos of New Mexico. Certain treaties negotiated by tribes and laws in Nevada guarantee Native Americans' right to harvest pine nuts, and the state of New Mexico protects the use of the word piñon for use with pine nuts from certain species of indigenous New Mexican pines.

A clinical study that includes some, but not all, of the eligible patients identified by the researchers during the study registration period. This type of study does not usually have a control group. (NCI) Non-inferiority trial

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network